NTRA Stock Analysis & Forecast (2026)

Natera, Inc. Healthcare Diagnostics & Research
$208.37
Current Price
67%
Buy
View Plans
Data refreshed: April 22, 2026

Key Financial Metrics

Market Cap
$29.53B
Revenue Growth
39.8%
Gross Margin
64.7%
Net Margin
-9.0%
Return on Equity
-14.3%
Debt/Equity
0.13

AI Analysis Summary

Natera, Inc. (NTRA) is a Healthcare company in the Diagnostics & Research industry with a 67% Buy Score. Key strengths include Revenue Growth (39.8%), Gross Margin (64.7%), Debt/Equity (0.13). Areas to watch: Net Margin (-9.0%), Return on Equity (-14.3%). Our AI evaluates 8 fundamental categories including revenue growth, margin quality, balance sheet strength, cash flow generation, return on capital, and valuation metrics.

Revenue Growth: Strong Gross Margin: Excellent Net Margin: Negative Return on Equity: Negative Debt/Equity: Low Risk

This analysis is generated by StrongBuyAnalytics AI using publicly available financial data from SEC filings, earnings reports, and market feeds. It is not personalized investment advice. See our methodology and disclaimer.

NTRA Fundamental Analysis Report
PDF Report Preview
67%
Strong Buy Score
  • 8 Fundamental Categories Analyzed
  • Revenue & Growth Trends
  • Margin & Profitability Analysis
  • Balance Sheet Strength
  • Cash Flow Quality
  • Valuation Assessment
  • AI-Powered Investment Insights
Get Your Free NTRA Report

How It Works: AI Stock Analysis in 60 Seconds

See how our AI analyzes NTRA fundamentals to generate buy/sell signals and Strong Buy Scores.

Why NTRA Has a 67% Score

Our AI evaluates Natera, Inc.'s fundamentals across multiple dimensions. Here is what is driving the current Buy rating:

Recent Catalysts for NTRA

Key developments and data points that may impact Natera, Inc.'s trajectory:

Wall Street consensus target is $258.00 (+23.8% from current price), based on 18 analyst estimates.
Analyst consensus recommendation: Strong Buy.
Institutional ownership at 94.7% — strong smart-money backing.

NTRA vs. Peers

How Natera, Inc. stacks up against comparable Healthcare companies on key metrics:

Ticker Price Market Cap P/E Rev Growth Net Margin ROE
NTRA $208.37 $29.53B 39.8% -9.0% -14.3%
JNJ $226.16 $545.02B 20.5x 9.9% 21.8%
UNH $346.01 $314.06B 26.2x 12.3% 2.7% 12.5%
PFE $27.31 $155.35B 20.1x -1.2% 12.4% 8.9%
MRK $112.56 $278.29B 15.5x 5.0% 28.1% 36.9%

Main Risks for NTRA Investors

Every investment carries risk. Here are the specific risk factors our analysis identified for Natera, Inc.:

Net Margin (-9.0%)
Return on Equity (-14.3%)
High beta of 1.68 means the stock is 68% more volatile than the market — expect larger drawdowns in corrections.
Short interest is elevated with a 3.9-day cover ratio, indicating bearish bets against the stock.

Generate the full PDF report for a detailed risk-reward framework and bear-case scenarios.

NTRA Balance Sheet & Cash Flow

A snapshot of Natera, Inc.'s financial health based on the most recent filings:

Total Cash
$1.08B
Total Debt
$214.38M
Current Ratio
3.39
FCF Yield
0.5%
EBITDA
$-271,427,008
Operating Margin
-3.4%

Data sourced from the latest SEC filings. Generate the full PDF report for detailed balance sheet and cash flow commentary.

NTRA Valuation Snapshot

Price / Book
17.0x
High intangible value
Analyst Target (Mean)
$258.00
Range: $190 – $300
52-Week Price Range — NTRA is trading at 61% of its range
$131.81 (52W Low) $256.36 (52W High)

Is NTRA a Buy Right Now?

Based on our AI-powered fundamental analysis, NTRA has a Strong Buy Score of 67%, earning a "Buy" rating. This score synthesizes 8 key financial metrics to provide an objective investment signal.

Moderate Buy Signal

Natera, Inc. shows mixed fundamentals with some strengths and areas to monitor. Positives include Revenue Growth (39.8%). Watch for Net Margin (-9.0%).

NTRA AI Buy & Sell Signals Explained

Our AI analyzes Natera, Inc.'s financial statements to generate buy/sell signals based on quantitative metrics, not market sentiment or news headlines. Here's what drives the 67% score:

  • Revenue Growth: 39.8% year-over-year (above average)
  • Gross Margin: 64.7% (strong pricing power)
  • Net Margin: -9.0% (unprofitable)
  • Return on Equity: -14.3% (negative returns)

Generate the full PDF report for complete category-by-category scoring and AI-powered investment recommendations.

Key Support / Demand Zones

Technical traders can view real-time demand and supply zones for NTRA on our Demand Zones page. These zones identify key price levels where institutional buying or selling has historically occurred.

With NTRA currently trading at $208.37, our system monitors proximity to these critical levels and can alert you when the stock approaches support or resistance zones.

Subscribe to demand zone alerts to receive real-time notifications when NTRA reaches key technical levels.

Earnings & Revenue Outlook

Natera, Inc. operates in the Healthcare sector, specifically in Diagnostics & Research. Understanding earnings trends is crucial for forecasting NTRA's trajectory.

Current revenue growth of 39.8% significantly outpaces the average company. This strong growth trajectory supports a higher valuation multiple.

Visit our Earnings Calendar to track upcoming NTRA earnings dates and historical beat/miss patterns. Sign up for earnings alerts to get notified before announcements.

NTRA Stock Forecast (Next 3–12 Months)

Our AI projects NTRA's trajectory based on current fundamentals and historical patterns. With a 67% Strong Buy Score, here's what the data suggests:

Mixed Outlook: Natera, Inc. shows moderate fundamental strength. Revenue growth at 39.8% is positive but warrants monitoring. The stock may trade sideways or experience modest gains depending on execution and market conditions.

For a complete 12-month price forecast with specific bull/bear scenarios, generate the full PDF report.

Valuation Metrics (P/E, Growth, Margins)

Understanding valuation is critical for determining if NTRA is fairly priced. Here's the current snapshot:

  • Market Capitalization: $29.53B
  • Debt/Equity: 0.13 (conservative balance sheet)

Our AI weighs these metrics against growth rates and margin quality to determine if NTRA offers compelling risk-adjusted returns at current prices.

Bull Case for NTRA

Here's why investors are bullish on Natera, Inc.:

  • Revenue Growth (39.8%)
  • Gross Margin (64.7%)
  • Debt/Equity (0.13)

While these positives exist, investors should weigh them against the risks outlined in the bear case below.

Bear Case & Risks for NTRA

Every investment carries risk. Here are potential concerns for NTRA investors:

  • Net Margin (-9.0%)
  • Return on Equity (-14.3%)

The full PDF report includes a detailed bear case analysis with specific risk ratings for each category.

Summary / 12-Month Outlook

NTRA Summary: Natera, Inc. earns a 67% Buy Score based on AI analysis of fundamental data. Trading at $208.37 with a $29.53B market cap, the stock presents a balanced risk/reward profile for the coming year.

Bull Case: Revenue Growth (39.8%), Gross Margin (64.7%)

Watch: Net Margin (-9.0%), Return on Equity (-14.3%)

For the complete analysis with specific price considerations, growth projections, and AI-powered buy/hold/sell recommendations, generate your free NTRA PDF report.

Learn More About Stock Analysis

Deepen your understanding of the concepts used in this NTRA analysis:

Fundamental Analysis Guide

Learn how to evaluate stocks using financial statements and key metrics.

Understanding P/E Ratio

What P/E ratio tells you about a stock's valuation and growth expectations.

Return on Equity (ROE)

Why ROE matters for stock selection and how to interpret it.

Stock Valuation Methods

Compare DCF, P/E, and other approaches to value stocks like NTRA.

What Are Demand Zones?

Find key support and resistance levels for NTRA and other stocks.

How to Read Earnings Reports

Understand earnings per share, revenue surprises, and guidance.

Related Tools for NTRA

Demand Zone Analyzer NTRA Live Chart NTRA SEC Filing News Earnings Calendar Institutional Ownership Sector Scanner Average Down Calculator

NTRA SEC Filing News

Latest SEC filings for NTRA explained in plain English — insider buys/sells (Form 4), proposed sales (Form 144), material events (8-K), and quarterly & annual reports.

Loading recent SEC filings…
View all NTRA SEC Filing News →

Frequently Asked Questions about NTRA

Is NTRA a good buy right now?
NTRA currently has a Strong Buy Score of 67% (Buy). NTRA shows moderate buy signals. The stock has mixed fundamentals worth reviewing in detail. Generate a free PDF report for specific buy/hold/sell recommendations.
What is the NTRA stock forecast for 2026?
Our AI forecasts NTRA based on current fundamentals: revenue growth of 39.8%, net margin of -9.0%. The 67% Strong Buy Score reflects our outlook combining growth trajectory, margin quality, and valuation. See the full 12-month projection in your PDF report.
What are key support and resistance levels for NTRA?
View real-time NTRA demand zones (support) and supply zones (resistance) on our Demand Zones page. With NTRA currently at $208.37, you can see how close the stock is to key technical levels. Subscribe to get alerts when NTRA approaches these zones.
How do NTRA fundamentals compare to peers?
Natera, Inc. operates in the Healthcare sector. Key metrics for peer comparison: Gross margin 64.7%, ROE -14.3%, Debt/Equity 0.13. The 67% Strong Buy Score factors in how these metrics stack up against industry averages. Data is refreshed daily.
Is the NTRA analysis PDF report free?
Yes! Your first NTRA fundamental analysis report is completely free with no credit card required. The PDF includes the full Strong Buy Score breakdown, all 8 fundamental categories analyzed, AI-powered insights, and specific investment recommendations. Additional reports are available through our subscription plans starting at $24/month.
What is Natera, Inc.'s market cap and P/E ratio?
Natera, Inc. (NTRA) has a market cap of $29.53B. These valuation metrics are key factors in our Strong Buy Score calculation. See all metrics in the PDF report for comprehensive valuation analysis.

This NTRA analysis is for educational and informational purposes only and does not constitute financial advice. All data is sourced from public filings and market feeds. Past performance does not guarantee future results. Read our full disclaimer.